Ionis announce plans for new Roche Phase 2 tominersen trial
Ionis Pharmaceuticals has announced that its partner Roche is designing a new Phase 2 trial to evaluate tominersen in Huntington's disease.
The statement - which you can read in full at - comes after dosing with the drug was halted last year as part of the Phase 3 GENERATION-HD1 study on the recommendation of the independent data monitoring committee.
Now new analyses has suggested that tominersen may benefit younger adult patients with lower disease burden. Scottish Huntington’s Association has cautiously welcomed the news, pending fuller analysis of the evidence to be presented at a webinar hosted by European Huntington Association (EHA) next week.
You are invited to join the webinar on Monday, 24 January, at 5pm UK time, when Lauren Boak PhD and Peter McColgan MD PhD from Roche will present key findings from the GENERATION-HD1 trial and the tominersen programme.
Register in advance to attend at:
In the meantime, please sign up to our mailing list at https://hdscotland.org/stay-in-touch/ to hear about latest developments.